Neurizon Therapeutics (ASX:NUZ) submitted an investigational new drug application with the US Food and Drug Administration to conduct a phase 2/3 trial of its drug candidate, NUZ-001, for amyotrophic lateral sclerosis, according to a Wednesday filing with the Australian bourse.

Once approved, the Healey ALS Platform study will start patient enrollment in the first half of next year, the filing said.

Amyotrophic lateral sclerosis is a motor neuron disease characterized by the progressive degeneration of nerve cells in the spinal cord and brain, the Johns Hopkins Medicine website showed.

The company's shares were down 3% in recent Wednesday trade.

Price (AUD): $0.17, Change: $-0.01, Percent Change: -2.86%